Potential result, complementary diagnosis, financing, technological environment and target solutions that drive growth

DUBLIN, March 28, 2022 /PRNewswire/ — The “Market forecasts for immuno-oncology diagnostics with COVID-19 impact and updates” Report has been added to ResearchAndMarkets.com offering.

Research and Markets Logo

Research and Markets Logo

Diagnostics, complementary diagnostics, are driving the success of Immuno-Oncology Therapeutics. A whole new segment of the diagnostics industry is being created and it is not a small segment either.

It promises to grow dramatically. Histology, genomics and liquid biopsy are converging. An intricate web of pharmaceutical companies, diagnostic companies and instrumentation providers are vying for position in a new approach to conquering cancer. The approach appears to be working and showing great promise.

A revolution in cancer therapy is underway. New therapy based on the use of the body’s natural immune defenses is seeing unprecedented success, but diagnostics, especially biomarkers, are desperately needed to help select the appropriate therapy.

Technology advances faster than the market. The impact on the health care industry is huge. Tumor mutational burden? Checkpoint inhibitors? Cytokines?

Learn about the technology in easily understandable terms that explain the jargon. Find the opportunities and the traps. Understand the growth expectations and ultimate potential size of the market in this comprehensive new expanded report.

Key Topics Covered:

Cancer Immuno-Oncology Diagnosis Recent Advances

  • Lucence liquid biopsy test tracks changes in ctDNA from immune treatment

  • Qiagen and OncXerna Close Companion Dx Development Agreement

  • natera test to guide therapy for bladder cancer

  • Acquisition of Veracyte Halio to boost immuno-oncology activity

  • Freenome Eyes New Dx Possibilities

  • Oncocyte data have potential as a predictor of response to immunotherapy

  • OncoDNA uses HalioDx to expand to North America

  • Adaptive Biotechnologies, Q2 solutions agreement for the ImmunoSeq assay.

  • Qiagen Expands Its Immuno-Oncology Portfolio

  • Immune profile system redirected to fight COVID-19

  • PD-L1 Detection Patent Awarded to IncellDx

  • FDA approves CDx for trastuzumab

  • Promega Earns CE Mark for Microsatellite Instability IVD

  • ArcherDx partners with AstraZeneca for immuno-oncology

  • Germline results guide precision therapy

  • Agilent PD-L1 assay gains FDA approval

  • Bayer and OrigiMed Form Companion Diagnostics Development Alliance

  • Bio-Me to develop microbiome biomarker test for cancer immunotherapy

  • SkylineDx and BioInvent collaborate to characterize predictive immune signatures

  • Biocare Medical Launches 7 New IVD Antibodies

  • Oncocyte to acquire Insight Genetics for $12 million

  • Novigenix and BioLizard will develop a diagnostic algorithm based on NGS

  • Biodesix and Immodulon collaborate for the treatment of pancreatic cancer

  • Generex to merge with NuGenerex Immuno-Oncology

  • Cellgen Diagnostics and Genomic Testing Cooperative Partners to Develop Companion Diagnostics for Cancer Therapies

  • Hematogenix Launches FDA-Approved Immuno-Oncology Test for Triple Negative Breast Cancer

  • Icon Acquires MolecularMD

market trends

Growth Drivers

  • potential outcome

  • Complementary Diagnostics

  • Money

  • Technological environment

  • Target Solutions

Factors that limit growth

Development of diagnostic technology

  • Combinations – Problems and Complexity

  • Changing role of diagnostics

  • Multiplexing and Foundation One

  • The disruptive dynamic

  • The race for biomarkers

  • the next five years

Immunotherapy – Immune Technologies Guide

innate immune system

  • surface barriers

  • Inflammation

  • complementary system

  • Cellular barriers

  • natural killer cells

adaptive immune system

Immuno-oncology diagnosis

  • Checkpoint assays

  • Cytokine assays

  • Genomic germ line

  • genomic tumor

  • tumor microenvironment

Key Immuno-Oncology Company Profiles

  • 10x Genomics, Inc.

  • Abbott Diagnosis

  • AccuraGen Inc.

  • adaptive biotechnologies

  • aethlon medical

  • Agena Bioscience, Inc.

  • Agilent/Dako

  • Anchor Dx

  • ANGLE plc

  • ApoCell, Inc.

  • ARUP Laboratories

  • asuragen

  • AVIVA Biosciences

  • Baylor Miraca Genetics Laboratories

  • Beckman Coulter Diagnosis

  • Becton, Dickinson and Company

  • BGI Genomics Co. Ltd.

  • biomatrix genetics

  • biochartis

  • biocept, inc.

  • biodesix inc.

  • biofluids

  • biogenex

  • BioIVT

  • Biolidics Ltd

  • Biomérieux diagnosis

  • Bioneer Corporation

  • Bio-Rad Laboratories, Inc.

  • Bio-Reference Laboratories

  • Biotechnology

  • Biovista

  • Bolidica

  • boreal genomics

  • Bristol board-myers-squibb

  • burning rock

  • cancer genetics

  • Caris Molecular Diagnosis

  • castle biosciences, inc.

  • CellMax Shelf Life

  • Cepheid (Danaher)

  • Charles River Laboratories

  • Chronix biomedical

  • Circulogene

  • Clinical Genomics

  • Cynvenius

  • Cytolumina Technologies Corp.

  • CytoTrack

  • Datar Cancer Genetics Limited

  • Diagnologix LLC

  • Diasorin SpA

  • enzo biochemistry

  • epic sciences

  • Epigenomics GA

  • scientific eurofins

  • Exosome Diagnosis

  • Exosome Sciences

  • fabric genomics

  • Fluidigm Corporation

  • Fluxion Biosciences

  • Medicine Foundation

  • free name

  • FUJIFILM Your Diagnosis

  • GeneFirst Ltd.

  • Genetron Holdings

  • GenomOncology

  • GILUPI Nanomedicine

  • Grail, Inc.

  • Guardian Health

  • haliodx

  • HansaBiomed

  • HeiScreen

  • helomic

  • discovery of the horizon

  • HTG Molecular Diagnostics

  • iCellate

  • illuminate

  • IncellDx

  • Invited

  • Integrated Diagnostics

  • Invite Corporation

  • Invivogene

  • Invivoscribe

  • Janssen Diagnosis

  • MDNA Life Sciences, Inc.

  • MDx Health

  • Menarini Silicon Biosystems

  • Millipore Sigma

  • miltenyi biotech

  • MIODx

  • scientific miR

  • Molecular MD

  • MyCartis

  • Myriad Genetics/Myriad RBM

  • NantHealth, Inc.

  • Natera

  • Neogenomics

  • new oncology

  • NGOBio

  • Novogene Bioinformatics Technology Co., Ltd.

  • oncocyte

  • OncoDNA

  • Ortho Clinical Diagnosis

  • Oxford Nanopore Technologies

  • panagene

  • Perkin Elmer

  • Personal Genome Diagnosis

  • Personal

  • price

  • PrecisionMed

  • promise

  • Qiagen GmbH

  • Rarecells SAS

  • RareCyte

  • Roche Molecular Diagnostics

  • screen cell

  • Sense Biosensing

  • serametrix

  • Siemens Healthineers

  • silicon biosystems

  • simfo GmbH

  • Singlera Genomics Inc.

  • sinngulomica

  • SkylineDx

  • Stratus Genomics

  • Sysmex Inosticos

  • Time Laboratories, Inc.

  • ThermoFisher Scientific Inc.

  • Thrive early detection

  • all medical

  • Trovagene

  • Willpower

  • Vortex Biosciences

For more information on this report, visit https://www.researchandmarkets.com/r/p4t8zu

Media Contact:

Research and Markets
laura woodSenior manager
press@researchandmarkets.com

For business hours EST call +1-917-300-0470
For US/Canada call toll free +1-800-526-8630
For GMT business hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

cision

cision

See original content:https://www.prnewswire.com/news-releases/global-immuno-oncology-diagnostics-markets-2022-2027-outcome-potential-companion-diagnostics-funding-technology-environment–target-solutions-driving-growth -301511851.html

SOURCE Research and Markets

Previous post Mid Penn Bancorp: 5 Goals for Personal Finance and Planning
Next post Turkey risks acting as a “safe haven” from sanctions for the Russians
%d bloggers like this: